BeyondSpring Inc. — FY2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 filing. Financial statements are prepared under U.S. GAAP and audited by Ernst & Young Hua Ming LLP, which issued an unqualified opinion.
Business context
BeyondSpring is a clinical-stage biopharmaceutical company with no approved products and no material product-sales revenue. Its lead candidate, Plinabulin, is being developed for chemotherapy-induced neutropenia (CIN), advanced non-small cell lung cancer (NSCLC), and immuno-oncology combinations. The company also has preclinical programs and a targeted protein degradation platform through subsidiary SEED.
Financial and liquidity highlights
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0.18 million | None |
| Research and development expense | $41.8 million | $31.3 million |
| General and administrative expense | $22.6 million | $9.0 million |
| Operating loss | $64.2 million | $40.3 million |
| Net loss | $63.8 million | $40.3 million |
| Net loss per share, basic and diluted | $2.03 | $1.55 |
| Cash used in operating activities | $43.7 million | $48.2 million |
| Cash and cash equivalents at year-end | $109.5 million | $35.9 million |
| Total liabilities | $25.2 million | $13.4 million |
Accumulated deficit reached $277.8 million, up from $216.8 million. The company reported $99.6 million of net current assets. Long-term loans totaled $2.17 million, comprising a China Construction Bank loan and a Paycheck Protection Program loan; lease liabilities totaled $2.15 million. No income tax benefit was recorded. Profit margins are not meaningful given the company’s development-stage operations and negligible revenue.
FY2020 operating expenses rose as R&D increased 33%, mainly from clinical-trial costs, share-based compensation and NDA support, while G&A increased 152%, reflecting pre-commercialization, commercial and executive staffing, incentive payments, share-based compensation and professional services. The net loss widened 58% year over year.
Financing activities provided $117.8 million of net cash in 2020; cash increased $73.6 million during the year. The company completed public and private equity offerings, issuing 11.24 million shares during 2020. Management stated that resources available at year-end were expected to fund operations and capital expenditures through the second quarter of 2022, but additional financing will be needed for further trials and commercialization. Future equity financing could dilute shareholders.
Material developments and outlook
- CIN: Management reported that the Phase 3 PROTECTIVE-2 trial met its primary endpoint: prevention of grade 4 neutropenia was 31.5% with Plinabulin plus pegfilgrastim versus 13.6% with pegfilgrastim alone (p=0.0015). The company reported positive key secondary endpoints. In March 2021, after the fiscal year, it submitted U.S. and China NDAs for this use.
- NSCLC: DUBLIN-3 completed enrollment of 559 patients. The filing expected final top-line Phase 3 data in mid-2021; the trial’s primary endpoint is overall survival. Earlier Study 101 did not show statistically significant overall-survival improvement in the intent-to-treat population; the favorable measurable-lesion subgroup analysis was small and not statistically significant.
- SEED/Lilly collaboration: SEED received $15 million in cash and an initial equity investment under its November 2020 collaboration with Lilly. The arrangement includes up to approximately $780 million in potential milestones and tiered royalties, which are contingent and not assured. Of the cash proceeds, $9.455 million was allocated to collaboration services, $5.267 million to preferred shares and $0.278 million to a forward liability. Only $0.18 million was recognized as 2020 revenue; $9.275 million was recorded as deferred revenue.
- Outlook: Management expects continued losses, negative operating cash flows, significant R&D spending and increased pre-commercialization and commercialization costs. It said current cash was sufficient to complete DUBLIN-3, but additional funding may be required for regulatory-requested studies and commercialization.
Risks, contingencies and unusual items
- Plinabulin is the company’s principal clinical asset; trial failure, additional FDA or NMPA study requirements, safety findings or delayed approval could materially impair prospects. Known potential Plinabulin adverse events include nausea, vomiting, fatigue, fever, tumor pain and transient blood-pressure elevation.
- COVID-19 disrupted enrollment in Ukraine and caused minor enrollment and data-processing delays; management said global enrollment in PROTECTIVE-2 and DUBLIN-3 was completed, but future regulatory, inspection and trial timelines remained uncertain.
- The company relies on contract research and manufacturing providers and identifies BASF as the sole supplier of Kolliphor HS15, a stabilizing agent in the current Plinabulin formulation. A supply interruption could require reformulation and delay development.
- BeyondSpring owns 57.97% of the Chinese subsidiary holding Plinabulin rights in China, so it does not own those rights outright. China-related regulatory, currency, dividend-repatriation and legal-enforcement risks are disclosed.
- Management reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2020; the auditor did not attest to internal controls. The filing also highlights limits on PCAOB inspection of auditors in China and related potential listing and investor risks.
- SEED’s Series A-2 preferred shares carry an 8% annual return and may be redeemable in installments beginning after November 10, 2025 at holders’ request; redemption is not guaranteed by BeyondSpring. No material legal proceedings were reported.
Important facts for investors to verify
- Regulatory status and review timelines for the CIN NDAs submitted in March 2021, including any requests for additional data or trials.
- Final DUBLIN-3 overall-survival results and whether the prespecified statistical threshold was met.
- Actual cash burn, financing needs and runway versus management’s stated second-quarter 2022 estimate; also assess dilution from the 2020 share issuance.
- Terms, milestones and revenue recognition of the Lilly-SEED collaboration, including the conditions for future payments and the preferred-share redemption exposure.
- Manufacturing supply continuity, particularly Kolliphor HS15, and the company’s ability to scale manufacturing if Plinabulin is approved.
- Clinical-trial evidence, safety data, reimbursement prospects and commercial preparedness; distinguish management’s market and efficacy claims from independently verified outcomes.